JPMorgan Chase & Co. Grows Holdings in Aura Biosciences, Inc. (NASDAQ:AURA)

JPMorgan Chase & Co. raised its position in Aura Biosciences, Inc. (NASDAQ:AURA) by 107.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 53,502 shares of the company’s stock after buying an additional 27,718 shares during the period. JPMorgan Chase & Co. owned approximately 0.11% of Aura Biosciences worth $477,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. American Century Companies Inc. acquired a new stake in Aura Biosciences during the 2nd quarter valued at approximately $119,000. SG Americas Securities LLC acquired a new stake in shares of Aura Biosciences during the third quarter worth approximately $169,000. The Manufacturers Life Insurance Company grew its position in shares of Aura Biosciences by 14.6% during the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after buying an additional 8,194 shares in the last quarter. Barclays PLC increased its stake in shares of Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after buying an additional 43,897 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Aura Biosciences by 26.3% in the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock valued at $545,000 after acquiring an additional 15,000 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a research report on Thursday, November 14th. Cowen restated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. BTIG Research lifted their target price on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. Finally, Scotiabank upped their price target on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Friday, October 18th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Stock Performance

Aura Biosciences stock opened at $7.85 on Wednesday. The firm’s 50 day moving average price is $8.33 and its two-hundred day moving average price is $8.92. The firm has a market cap of $392.11 million, a PE ratio of -4.54 and a beta of 0.30. Aura Biosciences, Inc. has a twelve month low of $6.63 and a twelve month high of $12.38.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. Equities analysts anticipate that Aura Biosciences, Inc. will post -1.67 EPS for the current fiscal year.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, insider Janet Jill Hopkins sold 11,822 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the completion of the transaction, the insider now owns 151,693 shares of the company’s stock, valued at $1,419,846.48. This represents a 7.23 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the sale, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,778 shares of company stock worth $240,706 over the last ninety days. Company insiders own 5.40% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.